Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
12. November 2024 19:01 ET
|
Nxera Pharma
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd....
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
05. November 2024 02:00 ET
|
Nxera Pharma
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies...
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
01. November 2024 02:30 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational...
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
23. Oktober 2024 03:00 ET
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won...
Nxera Pharma to Host R&D Day 2024
18. Oktober 2024 05:38 ET
|
Nxera Pharma
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date:...
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
01. Oktober 2024 02:04 ET
|
Nxera Pharma
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of...
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
01. Oktober 2024 02:02 ET
|
Nxera Pharma
QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024...
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
24. September 2024 02:06 ET
|
Nxera Pharma
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary...
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
13. September 2024 02:30 ET
|
Nxera Pharma
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesCancer Research UK’s Centre for...
Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
11. September 2024 06:52 ET
|
Nxera Pharma
ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency and had a favorable safety and tolerability profile with no observations of frequently reported...